{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:52:30Z","timestamp":1783749150114,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Chronic HCV infection causes substantial morbidity and mortality and, in co-infection with HIV, may result in immunological and virological failure following antiretroviral treatment. Estimates of HCV infection, co-infection with HIV and associated risk practices among PWID are scarce in Africa. This study therefore aimed at estimating the prevalence of HCV and associated risk factors among PWID in the largest metropolitan city in Tanzania to inform WHO elimination recommendations.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>An integrated bio-behavioral survey using respondent-driven sampling was used to recruit PWID residing in Dar es Salaam, Tanzania. Following face-to-face interviews, blood samples were collected for HIV and HCV testing. Weighted modified Poisson regression modeling with robust standard errors was used in the analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 611 PWID with a median age of 34\u00a0years (IQR, 29\u201338) were recruited through 4 to 8 waves. The majority of participants (94.3%) were males, and the median age at first injection was 24\u00a0years (IQR, 19\u201330). Only 6.55% (40\/611) of participants reported to have been enrolled in opioid treatment programs. The weighted HCV antibody prevalence was 16.2% (95%CI, 13.0\u201320.1). The corresponding prevalence of HIV infection was 8.7% (95%CI, 6.4\u201311.8). Of the 51 PWID who were infected with HIV, 22 (43.1%) were HCV seropositive. Lack of access to clean needles (adjusted prevalence ratio (APR), 1.76; 95%CI, 1.44; 12.74), sharing a needle the past month (APR, 1.72; 95%CI, 1.02; 3.00), not cleaning the needle the last time shared (APR, 2.29; 95%CI, 1.00; 6.37), and having unprotected not using a transactional sex (APR, 1.87; 95%CI, 1.00; 3.61) were associated with increased risk of HCV infection. On the other hand, not being on opioid substitution therapy was associated with 60% lower likelihood of infection.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The HCV antibody prevalence among PWID is lower than global estimates indicating potential for elimination. Improving access to safe injecting paraphernalia, promoting safer injecting practices is the focus of prevention programing. Screening for HIV\/HCV co-infection should be intensified in HIV care, opioid substitution programs, and other point of care for PWID. Use of direct-acting antiretroviral treatment would accelerate the achievement of hepatitis infection elimination goal by 2030.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12954-019-0346-y","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T10:01:58Z","timestamp":1576490518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["HIV\/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination"],"prefix":"10.1186","volume":"16","author":[{"given":"Germana Henry","family":"Leyna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Makyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mwijage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ramadhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Likindikoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mucho","family":"Mizinduko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melkizedeck Thomas","family":"Leshabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re","family":"Moen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3768-0225","authenticated-orcid":false,"given":"Elia John","family":"Mmbaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"issue":"12","key":"346_CR1","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-1109X(1117)30375-30373","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Larney S. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207. https:\/\/doi.org\/10.1016\/S2214-1109X(1117)30375-30373.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"346_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/add.14393","volume":"114","author":"Jason Grebely","year":"2018","unstructured":"Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150\u201366. https:\/\/doi.org\/10.1111\/add.14393.","journal-title":"Addiction"},{"key":"346_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","volume":"29","author":"D Lavanchy","year":"2009","unstructured":"Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29:74\u201381. https:\/\/doi.org\/10.1111\/j.1478-3231.2008.01934.x.","journal-title":"Liver Int"},{"issue":"4","key":"346_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1440-1746.2002.02730.x","volume":"17","author":"GJ Dore","year":"2002","unstructured":"Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol. 2002;17(4):423\u201330.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"346_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2009.1011.1009","volume":"14","author":"HS Te","year":"2010","unstructured":"Te HS. JD: epidemiology of hepatitis B and C viruses: a global overview. Clinical Liver Disease. 2010;14(1):1\u201321, vii. https:\/\/doi.org\/10.1016\/j.cld.2009.1011.1009.","journal-title":"Clinical Liver Disease"},{"issue":"2","key":"346_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/OLQ.0000000000000555","volume":"44","author":"EJMK Mmbaga","year":"2017","unstructured":"Mmbaga EJMK, Makyao N, Leshabari M. Prevalence and predictors of human immunodeficiency virus and selected sexually transmitted infections among people who inject drugs in Dar es Salaam, Tanzania: a new focus to get to zero. Sex Transm Dis. 2017;44(2):79\u201384.","journal-title":"Sex Transm Dis"},{"issue":"6","key":"346_CR7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrgastro.2014.1017","volume":"11","author":"JY Chen","year":"2014","unstructured":"Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11(6):362\u201371. https:\/\/doi.org\/10.1038\/nrgastro.2014.1017.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"346_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12072-015-9691-4","volume":"10","author":"MSP Mandorfer","year":"2016","unstructured":"Mandorfer MSP, Steiner S, Reiberger T, Peck-Radosavljevic M. Advances in the management of HIV\/HCV coinfection. Hepatol Int. 2016;10(3):424\u201335.","journal-title":"Hepatol Int"},{"issue":"4","key":"346_CR9","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/hep.510300409","volume":"30","author":"BY BM","year":"1999","unstructured":"BM BY, Di Martino V, Charlotte F. Azria F Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology. 1999;30(4):1054\u20138 doi.org\/1010.1002\/hep.510300409.","journal-title":"Hepatology"},{"issue":"4","key":"346_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hep.20626","volume":"41","author":"JA Pineda","year":"2005","unstructured":"Pineda JA, Romero-G\u00f3mez M, D\u00edaz-Garc\u00eda F, Gir\u00f3n-Gonz\u00e1lez JA, Montero JL, Torre-Cisneros J, Andrade RJ. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41(4):779\u201389.","journal-title":"Hepatology"},{"key":"346_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.drugpo.2017.1005.1043","volume":"45","author":"BH Lambdin","year":"2017","unstructured":"Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, Kral AH. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Int J Drug Policy. 2017;45:64\u20139. https:\/\/doi.org\/10.1016\/j.drugpo.2017.1005.1043.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"346_CR12","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1111\/jvh.12966","volume":"25","author":"Zameer Mohamed","year":"2018","unstructured":"Mohamed Z, Rwegasha, J., Kim, J. U., Shimakawa, Y., Poiteau, L., Chevaliez, S., \u2026 Lemoine, M: The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania. J Viral Hepat 2018, 25(12):1438\u20131445. doi:https:\/\/doi.org\/10.1111\/jvh.12966.","journal-title":"Journal of Viral Hepatitis"},{"key":"346_CR13","doi-asserted-by":"crossref","unstructured":"Natasha K Martin KJ, Matthias an der Heiden, Christoph Boesecke, Anders Boyd, Knud Schewe, Axel Baumgarten, Thomas Lutz, Stefan Christensen, Alexander Thielen, Stefan Mauss, J\u00fcrgen K Rockstroh, Britt Skaathun, Patrick Ingiliz: Eliminating hepatitis C virus among human immunodeficiency virus\u2013infected men who have sex with men in Berlin: a modeling analysis. J Infect Dis 2019, 220(10):1635\u20131644.","DOI":"10.1093\/infdis\/jiz367"},{"key":"346_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jpeds.2018.1012.1012","volume":"207","author":"JBA Nguyen","year":"2019","unstructured":"Nguyen JBA, Jhaveri R. Cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with hepatitis C virus infection. J Pediatr. 2019;207:90\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2018.1012.1012.","journal-title":"J Pediatr"},{"key":"346_CR15","volume-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C Virus Infection","author":"Organization. WH","year":"2018","unstructured":"Organization. WH. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C Virus Infection. Geneva: World Health Organization; 2018."},{"key":"346_CR16","doi-asserted-by":"publisher","unstructured":"Chaillon AMS, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One. 2019;14(6):e0217964. https:\/\/doi.org\/10.1371\/journal.pone.0217964.eCollection.2019.","DOI":"10.1371\/journal.pone.0217964.eCollection.2019"},{"key":"346_CR17","unstructured":"Statistics NBo: Tanzania HIV Impact Survey 2016-2017: Preliminary findings. In. Dar es Salaam: NBS, NACP; 2017."},{"issue":"1","key":"346_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1467-9531.2009.01216.x","volume":"39","author":"C Wejnert","year":"2009","unstructured":"Wejnert C. An emprerical test of respondent-driven sampling: point estimates, variance, degree measures, and out-of equilibrium data. Sociol Methodol. 2009;39(1):73\u2013116. https:\/\/doi.org\/10.1111\/j.1467-9531.2009.01216.x.","journal-title":"Sociol Methodol"},{"issue":"2","key":"346_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2307\/3096941","volume":"44","author":"D Heckathorn","year":"1997","unstructured":"Heckathorn D. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174\u201399.","journal-title":"Soc Probl"},{"key":"346_CR20","doi-asserted-by":"publisher","unstructured":"Bernd Schulte CSS, Strada L, Rosenkranz M, Sch\u00e4fer I, Verthein U, Reimer J. Hepatitis C virus prevalence and incidence in a large nationwide sample of patients in opioid substitution treatment in Germany: a prospective cohort study. Clin Infect Dis. 2019; https:\/\/doi.org\/10.1093\/cid\/ciz661.","DOI":"10.1093\/cid\/ciz661"},{"issue":"3","key":"346_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/add.14012","volume":"113","author":"LMS Platt","year":"2018","unstructured":"Platt LMS, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Bruneau J, Hickman M. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545\u201363. https:\/\/doi.org\/10.1111\/add.14012.","journal-title":"Addiction"},{"key":"346_CR22","doi-asserted-by":"publisher","unstructured":"Martin NK, Hickman, M., Hutchinson, S. J., Goldberg, D. J., & Vickerman, P: Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013, 57(suppl 2):S39\u2013S45. doi:https:\/\/doi.org\/10.1093\/cid\/cit1296.","DOI":"10.1093\/cid\/cit1296"},{"issue":"10","key":"346_CR23","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1360-0443.2006.01543.x","volume":"101","author":"L Maher","year":"2006","unstructured":"Maher L, Jalaludin B, Chant GK, Jayasuriya R, Sladden T, Kaldor MJ, Sargent PL. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006;101(10):1499\u2013508.","journal-title":"Addiction"},{"issue":"4","key":"346_CR24","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"MHK GJ","year":"2013","unstructured":"GJ MHK, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342. https:\/\/doi.org\/10.1002\/hep.26141.","journal-title":"Hepatology"},{"issue":"1","key":"346_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","volume":"44","author":"NSM Br\u00e4u","year":"2006","unstructured":"Br\u00e4u NSM, R\u00edos-Bedoya CF, Fern\u00e1ndez-Carbia A, Paronetto F, Rodr\u00edguez-Orengo JF, Rodr\u00edguez-Torres M. Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44(1):47\u201355 Epub 2005 Jul 2027.","journal-title":"J Hepatol"},{"key":"346_CR26","unstructured":"Programme NAC: Comprehensive Guideline for HIV prevention among Key Population in Tanzania. . In. Dar es Salaam, NACP; 2016."},{"key":"346_CR27","first-page":"129","volume":"5","author":"MJSA Dahoma","year":"2006","unstructured":"Dahoma MJSA, Abdool R. HIV and substance abuse: the dual epidemics challenging Zanzibar. Afr J Drugs Alcohol Studies. 2006;5:129\u201338.","journal-title":"Afr J Drugs Alcohol Studies"},{"issue":"6","key":"346_CR28","doi-asserted-by":"publisher","first-page":"e67062","DOI":"10.1371\/journal.pone.0067062","volume":"8","author":"Barrot H. Lambdin","year":"2013","unstructured":"Lambdin BH BR, Chang O Identifying programmatic gaps: inequities in harm reduction service utilization among male and female drug users in Dar es Salaam, Tanzania PLoS One 2013, 8(6):e67062.","journal-title":"PLoS ONE"},{"key":"346_CR29","doi-asserted-by":"publisher","unstructured":"Mlunde LBSB, Mbwambo JK. Correlates of health care seeking behaviour among people who inject drugs in Dar es Salaam, Tanzania. Int J Drug Policy. 2016;30. https:\/\/doi.org\/10.1016\/j.drugpo.2015.12.012:66-73.","DOI":"10.1016\/j.drugpo.2015.12.012:66-73"},{"issue":"3","key":"346_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.2008.79.338","volume":"79","author":"MWMS Ross","year":"2008","unstructured":"Ross MWMS. Kilonzo GP drug use careers and blood-borne pathogen risk behavior in male and female Tanzanian heroin injectors. Am J Trop Med Hyg. 2008;79(3):338\u201343.","journal-title":"Am J Trop Med Hyg"},{"key":"346_CR31","doi-asserted-by":"publisher","unstructured":"MS REA, Mbwambo JK, Lambdin BH, Voets A, Pont S, Maruyama H, Kilonzo GP. An overview of HIV prevention interventions for people who inject drugs in Tanzania. Adv Prev Med. 2013;183187. https:\/\/doi.org\/10.1155\/2013\/183187):183-187.","DOI":"10.1155\/2013\/183187):183-187"},{"issue":"2","key":"346_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11904-010-0043-7","volume":"7","author":"SASJ Strathdee","year":"2010","unstructured":"Strathdee SASJ. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for intervention. Current HIV\/AIDS Report. 2010;7(2):99\u2013106.","journal-title":"Current HIV\/AIDS Report"},{"key":"346_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.drugpo.2016.01.012","volume":"30","author":"Sophia Zamudio-Haas","year":"2016","unstructured":"Zamudio-Haas S mB, Saleem H Generating trust: programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania. Int J Drug Policy 2016, 30:43\u201351.","journal-title":"International Journal of Drug Policy"},{"issue":"11","key":"346_CR34","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.drugpo.2015.05.008","volume":"26","author":"Joseph S. Doyle","year":"2015","unstructured":"Doyle JS. AE, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME.: Global policy and access to new hepatitis C therapies for people who inject drugs. Int J Drug Policy 2015, 26(11):1064\u20131071.","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"346_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.drugalcdep.2013.04.012","volume":"132","author":"MRT Harris","year":"2013","unstructured":"Harris MRT. Injecting practices in sexual partnerships: hepatitis C transmission potentials in a \u2018risk equivalence\u2019 framework. Drug Alcohol Depend. 2013;132(3):617\u201323.","journal-title":"Drug Alcohol Depend"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0346-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-019-0346-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-019-0346-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:58:18Z","timestamp":1607561898000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-019-0346-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1186\/s12954-019-0346-y","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Research and Publication Committee of the Muhimbili University of Health and Allied Sciences, and permission to conduct the study was thereafter obtained from the municipal authorities. Written informed consent was obtained from participants before the interview commenced or blood sample collection. Participants also received health education about safe injecting and sexual behaviors at the end of interview and blood collection. All participants who tested positive for HIV and HCV were contacted and referred to the University teaching hospital (Muhimbili National Hospital) for further care and treatment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}